Prostate Cancer

Positive Phase I Data of 177Lu rhPSMA-10.1 Supports Phase II Trial for mCRPC
Early phase I data on lutetium (177Lu) rhPSMA-10.1 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has demonstrated an encouraging safety profile for the novel radioligand therapy. Developed by Blue Earth Therapeutics Ltd, 177Lu rhPSMA-10.1 was administered to patients in the phase I trial in July. Radiation dosimetry that was conducted for up to 3 cycles revealed high radiation doses absorbed by the tumor relative to the dose received by key normal organs, including the kidneys and salivary glands. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Localized
Localized

Conference Coverage

Advertisement
Advertisement
Latest News